Immune Response Against 2, 4‐Dinitrofluorobenzene‐Induced Atopic Dermatitis‐Like Clinical Manifestation is Suppressed by Spermidine in NC⁄Nga Mice. (April 2015)

• Record Type: Journal Article
• Authors: Kim, G.‐D.; Kim, T.‐H.; Park, Y. S.; Ahn, H.‐J.; Cho, J.‐J.; Park, C.‐S.
• Is Part Of: Scandinavian journal of immunology. Volume 81:Number 4(2015:Apr.)
• Page Start: 221
• Page End: 228
• Publication Date: 2015-04
• Subjects: Immunology -- Periodicals; 571.96
• DOI: 10.1111/sji.12274
• Languages: English
• ISSNs: 0300-9475

Abstract

Abstract: Of the biogenic polyamines, spermidine is a natural constituent of living cells and organisms. Spermidine is associated with regulation of cell growth, proliferation and differentiation, and with the suppression of oxidation and inflammation. Atopic dermatitis (AD) is a chronic inflammatory skin disease that has a complex and multiple pathogenesis, which includes genetic abnormality, modified or abnormal immune response and the production of nitric oxide and reactive oxygen species. We investigated whether spermidine can relieve AD‐like clinical manifestation induced by the continual application of 2, 4‐dinitrofluorobenzene (DNFB) in NC⁄Nga mice. Spermidine at concentrations of 1 or 10 mg/kg reduced increasing ear swelling and attenuated oedema, haemorrhage and hyperkeratosis in AD‐like skin lesions. Repetitive application of DNFB induced inflammatory cell infiltration to skin lesions, whereas intraperitoneal injection of spermidine inhibited DNFB‐evoked infiltration of eosinophils, mast cells and T lymphocytes. Furthermore, spermidine suppressed mast cell degranulation and production of interferon‐gamma by activated CD4 + T cells in AD‐like skin lesions. Spermidine may be a potential therapeutic agent for treatment of AD.